Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BioInvent, ThromboGenics license cancer antibody to Roche; terminated

Executive Summary

Antibody producer BioInvent International AB and partner ThromboGenics NV (focused on vascular disease therapeutics) have licensed Roche exclusive worldwide development and marketing rights to their Phase I TB403, an anti-placental growth factor (PlGF) antibody for advanced cancer. The licensers retain co-promotion rights in Nordic, Baltic, and Benelux countries.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies